Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small-molecule therapeutics. The company focuses on addressing age-related neurodegenerative diseases and disorders of the central nervous system (CNS) and retina. Its core mission is to develop disease-modifying treatments for patients suffering from these debilitating conditions, many of which currently have limited or no approved therapies. The company's headquarters are located in Purchase, New York.

The company's lead product candidate is zervimesine (also known as CT1812), an orally administered small molecule. Zervimesine is designed to protect neuronal synapses by preventing the binding of toxic oligomers of pathogenic proteins, such as beta-amyloid and alpha-synuclein, which are implicated in neurodegenerative disorders like Alzheimer's disease and dementia with Lewy bodies (DLB). Cognition Therapeutics leverages its proprietary NICE (Novel Improved Conditioned Extraction) screening platform to advance its pipeline beyond Alzheimer's disease into related indications.

Cognition Therapeutics became a publicly traded company on October 8, 2021, with its initial public offering (IPO) priced at $12.00 on the Nasdaq Global Market. Lisa Ricciardi serves as the Chief Executive Officer, a position she assumed in March 2020. Recent developments include the completion of enrollment for the Phase 2 START study in early Alzheimer's disease in November 2025. The company is also progressing zervimesine toward a registrational program for Dementia with Lewy Bodies psychosis, following positive Phase 2 SHIMMER data and discussions with the FDA in early 2026. The company's research and development efforts are significantly supported by non-dilutive funding, having secured approximately $171 million in cumulative grants, primarily from the National Institute on Aging (NIA).